Business Context and Reporting Period
This Form 8-K is filed by Graphite Bio, Inc. (not LENZ Therapeutics, Inc.) on November 10, 2021. The filing serves to announce the company's financial results and business progress for the third quarter ended September 30, 2021. The company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Global Market under the symbol GRPH.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing indicates the announcement of third-quarter 2021 results and recent business progress. No specific quantitative material changes versus the prior comparable period are disclosed in this document.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, and specific risk factors are contained within the press release (Exhibit 99.1) referenced in Item 2.02. This document explicitly states that the information in the exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the Exhibit 99.1 Press Release dated November 10, 2021.
- Confirm the details of "recent business progress" mentioned in the filing title.
- Note that the company is an emerging growth company, which may affect financial reporting standards.
- Review the full press release for any forward-looking statements or updated guidance not captured in this summary.